medcitynews.com

medcitynews.com
Share

medcitynews.com

 •  February 5

It was expected to be a perfunctory statehouse meeting — three lobbyists and a legislator discussing a proposal to educate Louisiana doctors about the price of drugs they prescribe. The bill seemed like a no-brainer in a country where even decades-old medicines can cost thousands and consumers are urged to make smart choices in buying health care....

medcitynews.com

 •  January 27

Clinical trials have a long rap sheet: expensive, slow, inaccurate, prone to failure. Patients, researchers, and investors wait impatiently for that elusive signal to show up – often in vain. But now, a UC San Francisco-led group may be developing a better way. Their solution is a platform trial called I-SPY – which stands for Investigating Series...

medcitynews.com

 •  January 13

The rise of companies such as Science 37 and Palantir combined with the FDA’s modified approach to regulation present new opportunities for the pharma industry to reduce the cost of drug development. But as Sanofi Chief Medical Officer Dr. Ameet Nathwani discussed in a fireside chat at StartUp Health Festival this week, figuring out how to...

medcitynews.com

 •  January 5

New Haven, Connecticut-based Arvinas has signed a new deal with Pfizer that could be worth up to $830 million. Announced Thursday, it follows in the footsteps of other multiyear, multimillion-dollar deals struck with Merck and Genentech, making Pfizer the third biopharma giant to partner with the 2013 startup. So what’s attracting the big fish?...

medcitynews.com

 •  December 10, 2017

Schenectady County, New York, is on track to pay 20 percent less on prescription drugs for its employees this year than in 2003. Flagler County, Florida, expects to save nearly $200,000 in 2017 on brand-name medicines for its 800 workers, its total drug costs having fallen by 10 percent since last year. Kokomo, Indiana, has found a way to save so...

medcitynews.com

 •  December 9, 2017

The U.S. Food and Drug Administration released draft guidance on digital health regulations designed to reduce ambiguity over the kinds of clinical decision support tools and patient decision support tools that needed to be reviewed by the FDA and those that didn’t. The regulator also issued final guidance on standardizing the way safety,...

medcitynews.com

 •  November 22, 2017

In the absence of new federal policies to tame break-the-bank drug prices, Massachusetts’ state Medicaid program hopes to road-test an idea both radical and market-driven. It wants the power to negotiate discounts for the drugs it purchases and to exclude drugs with limited treatment value. “This is a serious demonstration proposal,” said Sara...

medcitynews.com

 •  November 3, 2017

At a time of great political divide, there is one issue that unites many U.S. politicians and citizens: Drug prices are too high. President Donald Trump hinted at reforms with a series of colorful statements earlier this year. But ten months into his tenure, nothing has materialized at the federal level. Instead, state governments are leading the...

medcitynews.com

 •  October 17, 2017

Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kymriah and the 21 similar drugs in development — known as CAR T-cell therapies — will be far higher than many...

medcitynews.com

 •  October 14, 2017

In what could be a milestone development for clinical trial design by big pharma companies, Janssen has unveiled a set of tools to automate investigational products and data management in clinical trials, according to a news release. The goal is to improve medication adherence across multiple trial sites in different countries. The Integrated Smart...